Is This Coronavirus Drug Authorization Really Good News for Gilead?
Gilead Sciences (NASDAQ: GILD) is one step closer to winning the coronavirus treatment race. The U.S. Food and Drug Administration granted Gilead emergency use authorization last week for remdesivir in severe cases of COVID-19, the illness caused by the novel coronavirus. This isn't an approval -- trials to support an approval are ongoing -- but the authorization allows temporary broader use of remdesivir in hospitals across the country. This is great news for patients, and from a drug development point of view, it's also great news for Gilead.
But from a financial point of view, the picture isn't as clearly positive for the company.
Image source: Getty Images.
Source Fool.com
